Branded Formulations business has been a strong value builder for Biocon. Over the years, our affordable and differentiated portfolio in challenging disease spaces has built considerable brand equity with doctors and patients. A combination of products, patient needs, and physician support programs have enabled us to achieve market leadership in the therapeutic areas of Diabetology, Oncology, Immunology and Critical Care. We are focused on specialty therapy segments to build premium, commanding brands that stand out as innovative and highly differentiated. Biocon’s Branded Formulations business is making an impact in India through its wide portfolio of branded biosimilars, novel biologics and small molecule branded generics in the chronic disease segments of diabetes, cardiovascular, cancer, transplant and end-stage renal disease, immune disorders and other life-threatening conditions.